US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

US Bancorp DE boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOSFree Report) by 40.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,919 shares of the company’s stock after acquiring an additional 4,843 shares during the period. US Bancorp DE’s holdings in iTeos Therapeutics were worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ITOS. GSA Capital Partners LLP purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $263,000. Empowered Funds LLC lifted its position in iTeos Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 65,767 shares of the company’s stock valued at $671,000 after acquiring an additional 3,350 shares during the last quarter. Quest Partners LLC lifted its position in iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the last quarter. Intech Investment Management LLC purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $154,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $242,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ITOS shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. JPMorgan Chase & Co. decreased their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Finally, Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

Read Our Latest Research Report on iTeos Therapeutics

iTeos Therapeutics Stock Performance

ITOS stock opened at $7.32 on Monday. The firm has a market cap of $279.58 million, a PE ratio of -2.32 and a beta of 1.38. The firm’s fifty day moving average is $7.47 and its 200 day moving average is $9.00. iTeos Therapeutics, Inc. has a one year low of $6.67 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOSGet Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.13. Research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

(Free Report)

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Read More

Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOSFree Report).

Institutional Ownership by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.